Emerging Updates in Front-Line Immunotherapy for Unresectable Hepatocellular Carcinoma (uHCC) : Episode 3

Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

January 9, 2025

Opinion

Video

James J. Harding, MD, discusses the primary (overall survival [OS]) and secondary end points (overall response rate [ORR], duration of response [DOR]) of the CheckMate 9DW trial, and explores how the inclusion of the lenvatinib (LEN) arm informs the treatment landscape, as well as the safety profiles of first-line systemic immunotherapy in patients with uHCC, focusing on the most significant adverse events seen with nivolumab plus ipilimumab (NIVO + IPI).

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

Now Viewing

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

Video content above is prompted by the following:

As you review the trial, discuss the primary (OS) and secondary end points (ORR, DOR). How does inclusion of the LEN arm inform the treatment landscape?
Discuss the safety profiles with 1L systemic IO in patients with uHCC.
- What are the most significant adverse events seen with NIVO + IPI in CheckMate 9DW?